Tags : Rigel Pharmaceuticals

Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals

Vartika Singh January 24, 2019

Shots: Rigel to receive $30M upfront, $297.5M milestones including $20M on EMA approval of fostamatinib and royalties up to 30% on net sales. Grifols to get exclusive rights for fostamatinib in all indications including chronic ITP, autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN), in EU and Turkey Rigel will retain all global rights for […]Read More

Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for

Vartika Singh March 6, 2018

Shots: The approval is based on three FIT studies results assessing Tavalisse (100/150mg, bid) vs Placebo in 150 patients with chronic ITP in ratio 2:1 The FIT studies result: FIT-1 (NCT02076399) stable platelets response (SPR) (18% vs 0%); FIT-2 (NCT02076412) SPR (16% vs 4%); FIT-3 (23%) Tavalisse (fostamatinib disodium hexahydrate, PO) is a spleen tyrosine […]Read More

IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Sarepta Reports Two-Year Follow Up Results of SRP-9001 for Duchenne Muscular Dystrophy

Accord Launches Zercepac (biosimilar, trastuzumab) in the UK

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Insights+: COVID-19 Healthcare News Monthly Updates – September 2020

Regeneron’s REGN-COV2 Demonstrate Reduction in Viral Load and Improve Symptoms in Non-Hospitalized Patients with COVID-19

BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

CSL Behring’s Haegarda (C1 Esterase Inhibitor) Receives the US FDA’s Approval for Pediatric Patients with Hereditary Angioedema

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

Tags : Rigel Pharmaceuticals

Grifols Signs a License and Commercialization Agreement with Rigel Pharmaceuticals

Rigel Pharmaceuticals’ Tavalisse (fostamatinib disodium hexahydrate) Receives FDA Approval for

Latest Posts

Insights+: COVID-19 Healthcare News Monthly Updates – September 2020

Medtronic to Acquire Avenu Medical

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

Tags : Rigel Pharmaceuticals

Latest Posts

Categories

Related Topics